Literature DB >> 17545602

Kallikrein 4 is a proliferative factor that is overexpressed in prostate cancer.

Tove Irene Klokk1, Anette Kilander, Zhijun Xi, Håkon Waehre, Bjørn Risberg, Håvard E Danielsen, Fahri Saatcioglu.   

Abstract

Kallikrein 4 (KLK4) is a member of the human tissue KLK family. Whereas all other KLKs are secreted proteins with extracellular functions, KLK4 is primarily localized to the nucleus, indicating that it has a different function compared with other members of the KLK family. In addition, KLK4 expression is highly enriched in the prostate and is regulated by androgens. Here, we studied the possible functional role of KLK4 in prostate cancer cells and examined its expression at the protein level in prostate cancer specimens. Consistent with its mRNA expression, KLK4 protein is significantly overexpressed in malignant prostate compared with normal prostate. KLK4 expression is predominantly in the nucleus of basal cells in the prostate epithelium in keeping with its distribution in prostate cancer cells in vitro. Furthermore, adenovirus-mediated expression of KLK4 dramatically induces proliferation of prostate cancer cells, at least in part through significant alterations in cell cycle regulatory gene expression. Consistent with these data, small interfering RNA-mediated knockdown of endogenous KLK4 in LNCaP prostate cancer cells inhibits cell growth. These data identify KLK4 as the first member of the KLK family that is a proliferative factor with effects on gene expression and indicate that it may have an important role in prostate cancer development and progression.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17545602     DOI: 10.1158/0008-5472.CAN-06-4728

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  25 in total

1.  Molecular circuit involving KLK4 integrates androgen and mTOR signaling in prostate cancer.

Authors:  Yang Jin; Su Qu; Martina Tesikova; Ling Wang; Alexandr Kristian; Gunhild M Mælandsmo; Haiying Kong; Tianzhou Zhang; Carmen Jerónimo; Manuel R Teixeira; Erkan Yuca; Ibrahim Tekedereli; Kivanc Gorgulu; Neslihan Alpay; Anil K Sood; Gabriel Lopez-Berestein; Håvard E Danielsen; Bulent Ozpolat; Fahri Saatcioglu
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-24       Impact factor: 11.205

2.  Clinical significance of kallikrein-related peptidase-4 in oral cancer.

Authors:  Petros Papagerakis; Giuseppe Pannone; L I Zheng; Maria Athanassiou-Papaefthymiou; Yashuo Yamakoshi; Howard Stan McGuff; Omar Shkeir; Konstantinos Ghirtis; Silvana Papagerakis
Journal:  Anticancer Res       Date:  2015-04       Impact factor: 2.480

3.  A variant of the KLK4 gene is expressed as a cis sense-antisense chimeric transcript in prostate cancer cells.

Authors:  John Lai; Melanie L Lehman; Marcel E Dinger; Stephen C Hendy; Tim R Mercer; Inge Seim; Mitchell G Lawrence; John S Mattick; Judith A Clements; Colleen C Nelson
Journal:  RNA       Date:  2010-04-20       Impact factor: 4.942

4.  Pericellular regulation of prostate cancer expressed kallikrein-related peptidases and matrix metalloproteinases by cell surface serine proteases.

Authors:  Janet C Reid; Admire Matsika; Claire M Davies; Yaowu He; Amy Broomfield; Nigel C Bennett; Viktor Magdolen; Bhuvana Srinivasan; Judith A Clements; John D Hooper
Journal:  Am J Cancer Res       Date:  2017-11-01       Impact factor: 6.166

5.  Three dysregulated miRNAs control kallikrein 10 expression and cell proliferation in ovarian cancer.

Authors:  N M A White; T-F F Chow; S Mejia-Guerrero; M Diamandis; Y Rofael; H Faragalla; M Mankaruous; M Gabril; A Girgis; G M Yousef
Journal:  Br J Cancer       Date:  2010-03-30       Impact factor: 7.640

6.  Hypomaturation enamel defects in Klk4 knockout/LacZ knockin mice.

Authors:  James P Simmer; Yuanyuan Hu; Rangsiyakorn Lertlam; Yasuo Yamakoshi; Jan C-C Hu
Journal:  J Biol Chem       Date:  2009-05-06       Impact factor: 5.157

7.  DPPI may activate KLK4 during enamel formation.

Authors:  C E Tye; C T Pham; J P Simmer; J D Bartlett
Journal:  J Dent Res       Date:  2009-04       Impact factor: 6.116

Review 8.  Functional roles of human kallikrein-related peptidases.

Authors:  Georgia Sotiropoulou; Georgios Pampalakis; Eleftherios P Diamandis
Journal:  J Biol Chem       Date:  2009-10-09       Impact factor: 5.157

9.  Engineering a potent inhibitor of matriptase from the natural hepatocyte growth factor activator inhibitor type-1 (HAI-1) protein.

Authors:  Aaron C Mitchell; Deepti Kannan; Sean A Hunter; R Andres Parra Sperberg; Cheryl H Chang; Jennifer R Cochran
Journal:  J Biol Chem       Date:  2018-01-31       Impact factor: 5.157

10.  Quantification of Human Kallikrein-Related Peptidases in Biological Fluids by Multiplatform Targeted Mass Spectrometry Assays.

Authors:  Theano D Karakosta; Antoninus Soosaipillai; Eleftherios P Diamandis; Ihor Batruch; Andrei P Drabovich
Journal:  Mol Cell Proteomics       Date:  2016-07-01       Impact factor: 5.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.